Antenatal Corticosteroids for Late‑Preterm (34‑36 weeks) Gestation

Recommendations (Society for Maternal‑Fetal Medicine)

• The Society for Maternal‑Fetal Medicine issues a GRADE 1A recommendation to offer a single course of antenatal corticosteroids to singleton pregnancies at 34 + 0 to 36 + 6 weeks that meet high‑risk criteria for imminent preterm birth. [1][2]3

Expected Benefits

• In the Antenatal Late Preterm Steroids (ALPS) trial, treatment reduced the proportion of newborns requiring any respiratory support from 14.4 % to 11.6 % (relative risk 0.80; 95 % CI 0.66‑0.97). This corresponds to an absolute risk reduction of ≈ 3 %. 1
• The same trial showed a decrease in severe respiratory morbidity from 12.1 % to 8.1 % (RR 0.67; 95 % CI 0.53‑0.84). 1

Inclusion Criteria (ALPS Trial)

• Gestational age: singleton pregnancy between 34 + 0 and 36 + 6 weeks. [1][4]
• High probability of delivery within 7 days, defined as any of the following:
  
  • Preterm labor with intact membranes and cervical dilation ≥ 3 cm, or
  • Preterm premature rupture of membranes, or
  • Planned preterm delivery for maternal or fetal indications. 4

Contraindications & Cautions

Absolute Contraindication

• Pregestational diabetes mellitus – not recommended because of a significantly increased risk of neonatal hypoglycemia (GRADE 1C). [1][2]5

Relative Contraindication

• Low likelihood of delivery before 37 weeks – corticosteroids should be withheld (GRADE 1B). [1][3]

Risks to Counsel

• Neonatal hypoglycemia occurs more frequently after late‑preterm steroids; most cases are mild and resolve within 24 hours (≈ 93 %). 4
• Long‑term neurodevelopmental outcomes remain uncertain; no reliable data beyond the neonatal period for this gestational window (GRADE 1C). [1][2]6

Special Populations (Consider Use – GRADE 2C)

*All three groups are supported by the cited evidence. [1][2]5

Dosing Regimen

• Betamethasone 12 mg intramuscularly, administered as two doses 24 hours apart (total course = 2 doses). This regimen is preferred in U.S. practice. [1][2]4

Implementation Considerations

• Single course only – repeat courses in the late‑preterm period are not recommended. 1
• Absolute benefit modest – expect roughly a 3 % absolute reduction in need for respiratory support; decision‑making should balance this against hypoglycemia risk and unknown long‑term effects. 1

Betamethasone (Celestone Soluspan) for Late‑Preterm Fetal Lung Maturation

Indications & Timing

• Administer 12 mg of betamethasone intramuscularly in two doses 24 hours apart to pregnant individuals between 34 0⁄7 and 36 6⁄7 weeks gestation who have a high likelihood of delivering within the next 7 days. Society for Maternal‑Fetal Medicine recommendation; GRADE 1A. [7][8]

Dosage & Formulation

• The recommended regimen is 12 mg IM given twice, 24 hours apart. GRADE 1A. [7][8]
• Celestone Soluspan’s dual formulation (betamethasone phosphate + betamethasone acetate) is the preferred preparation, endorsed by the Society for Maternal‑Fetal Medicine with GRADE 1A evidence. 7

Inclusion Criteria (All Must Be Met)

• Singleton pregnancy at 34 0⁄7–36 6⁄7 weeks gestation. GRADE 1A. 8
• High probability of delivery within 7 days, defined by any of the following:

Absolute Contraindications

• Pregestational diabetes mellitus – associated with a markedly increased risk of severe neonatal hypoglycemia; GRADE 1C. 7
• Low probability of delivery before 37 weeks – risks outweigh benefits; GRADE 1B. [7][8]

Expected Benefits (Based on the ALPS Trial)

• Reduction in the proportion of neonates requiring respiratory support from 14.4 % to 11.6 % (relative risk 0.80; 95 % CI 0.66‑0.97). GRADE 1A. 8
• Reduction in severe respiratory morbidity from 12.1 % to 8.1 % (relative risk 0.67; 95 % CI 0.53‑0.84). GRADE 1A. 8

Risks & Safety Considerations

• Neonatal hypoglycemia occurs more frequently after antenatal steroids; 93 % of cases resolve within < 24 hours, indicating a generally mild, self‑limited condition. GRADE 1C. 7
• Long‑term neurodevelopmental outcomes remain uncertain; counseling of parents is advised, GRADE 1C. 7

Special Populations (Conditional Use – GRADE 2C)

• Pregnancies originally multiple but reduced to a singleton of ≥ 14 weeks gestation. GRADE 2C. 7
• Anticipated delivery within < 12 hours (e.g., imminent preterm birth). GRADE 2C. 7

Guideline Summary on Formulation Choice

• Despite emerging animal data questioning the necessity of the phosphate component, current clinical guidelines continue to recommend the dual‑formulation (Celestone Soluspan) because the pivotal ALPS trial, which demonstrated the respiratory benefits, used this preparation. GRADE 1A. [7][8]

Antenatal Betamethasone for Late‑Preterm PPROM

Recommendation Strength

Indications & Contraindications

Dosing Protocol

Expected Neonatal Benefits

Risks and Counseling Points

Clinical Implementation Checklist

Common Pitfalls